The primacy of clinical effectiveness for cost effectiveness analysis.
Casserly
I P
IP
Topol
E J
EJ
D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000191:economics* / Q000401:mortality / Q000628:therapy; D003362:Cost-Benefit Analysis; D017985:Dalteparin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D013577:Syndrome; D013997:Time Factors
D005343:Fibrinolytic Agents; D017985:Dalteparin